Progression Delaying Effect of Escitalopram in Alzheimer's Disease

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to test whether escitalopram would slow the brain atrophy in patients with mild to moderate AD over the 52-week period.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: H. Lundbeck A/S
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Age:40~90 years

• Education:not illiterate

• Clinical Dementia Rating (CDR):0.5~2

• Modified Hachinski Ischemic Score (Rosen et al., 1979):less than 4

• Dementia according to DSM-IV criteria

• Probable Alzheimer's disease according to NINCDS-ADRDA criteria

• Current ongoing donepezil medication at stable doses (5 ~ 10 mg/day) for at least 2 months

Exclusion criteria:

• Evidence of delirium, confusion or altered consciousness

• Evidence of Parkinson's disease, stroke, brain tumor and normal pressure hydrocephalus

• Evidence of infectious or inflammatory brain disease

• Evidence of serious cerebrovascular diseases

• Current major depressive disorder or other major psychiatric illnesses

• Evidence of serious or unstable medical illnesses which can significantly change cognitive state

• History of alcohol or other substance dependence

• Any antidepressant medications within the previous 4 weeks

• Absence of a reliable and cooperative collateral informant

• Any conditions which prohibit MRI scan, such as presence of pacemaker or cerebrovascular clip, and claustrophobia

• Evidence of focal brain lesions on MRI including lacunes and white matter hyperintensity lesions of grade 2 or more by Fazeka scale